Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iron + doxorubicin refers here to an experimental composite antineoplastic formulation in which iron oxide nanoparticles are combined with doxorubicin, specifically reported as Fe3O4 and doxorubicin encapsulated in Spora Lygodii for magnetically guided microrobot-based bladder cancer therapy. The therapeutic concept is that doxorubicin provides the cytotoxic antitumor effect through DNA intercalation and topoisomerase II inhibition, while the iron oxide component enables magnetic responsiveness for active targeting and localized delivery. Based on the provided context, this is not an approved named pharmaceutical product but a research-stage nanoparticle or microrobot drug-delivery formulation investigated for bladder cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iron + doxorubicin.